By AKB | UPSC Educator
⏱️ Reading Time: 8-10 minutes
Pathogen Access and Benefit Sharing UPSC Analysis GS2/3
Pathogen Access and Benefit Sharing (PABS) is a proposed global framework under the WHO to ensure that countries sharing viral or bacterial samples receive fair access to the resulting vaccines, diagnostics, and treatments developed using that data.
- Global health negotiators are debating the PABS framework to bridge the gap between rich and poor nations.
- Emergence of new variants highlights the danger of countries withholding data due to lack of trust.
- Ongoing tension between pharmaceutical intellectual property rights and public health needs.
- Global South countries are demanding legally binding commitments instead of voluntary donations.
Comprehensive guide on Pathogen Access and Benefit Sharing (PABS) for UPSC. Explore global health equity, vaccine nationalism, and WTO pandemic treaty challenges.
Important for UPSC Mains GS Paper 2 (International Relations/Health) and GS Paper 3 (Science and Technology/Intellectual Property Rights). High relevance for Essay topics on equity and global cooperation.
UPSC GS1/2/3/4 Topic: UPSC GS1/2/3/4 Topic, Pathogen Access and Benefit Sharing, WHO Pandemic Treaty, Global Health Governance, Vaccine Nationalism, Health Equity UPSC, Nagoya Protocol UPSC, International Relations UPSC, Global South Health Issues
- The Nagoya Protocol of 2010 addresses access to genetic resources and fair benefit distribution.
- During COVID-19, the COVAX initiative aimed to provide equitable access but faced significant supply shortages.
- Currently, most pathogen sharing is done through voluntary platforms like GISAID.
- The Pandemic Treaty negotiations seek to institutionalize 20% reserve production for WHO during health emergencies.
- Intergovernmental Negotiating Body (INB) meetings at WHO
- Drafting of the first-ever Pandemic Treaty
- Expansion of GISAID and other pathogen data-sharing platforms
- Rising threat of zoonotic diseases and AMR in the Global South
🧭 Introduction
In the world of global health, information is power. When a new virus emerges in a remote part of the world, scientists need samples to create life-saving vaccines. This exchange is known as pathogen sharing. However, a major conflict has emerged: the countries that provide these samples—often in the Global South—frequently find themselves at the back of the line when it comes to receiving the treatments made from them. This imbalance is the focus of the Pathogen Access and Benefit Sharing (PABS) framework currently under negotiation at the World Health Organization (WHO). For UPSC aspirants, this issue is not just about medicine; it is a complex intersection of International Relations (GS2), Science and Tech (GS3), and Ethics (GS4). It highlights the struggle between the commercial interests of developed nations and the humanitarian survival of developing ones.
🌍 Background
- The COVID-19 pandemic served as a wake-up call regarding health inequalities.
- Historical data shows that Low and Middle-Income Countries (LMICs) contribute the majority of pathogen data due to high biodiversity and surveillance.
- Initiatives like the Pandemic Influenza Preparedness (PIP) Framework already exist but are limited to specific viruses.
- Inequity during the 2009 H1N1 pandemic and recent Ebola outbreaks fueled the demand for a permanent, legally binding mechanism.
📊 Key Concepts
- Pathogen Access: The speed and ease with which scientific communities can access biological materials and genetic sequences.
- Benefit Sharing: The reciprocal return of products, technologies, or funds to the country that provided the genetic source.
- Vaccine Nationalism: When countries prioritize their own domestic needs over global cooperation during a health crisis.
- TRIPS Waiver: Proposals to waive intellectual property rights on medical goods during emergencies to boost local production.
✅ Advantages
- Global Surveillance: Guaranteed benefits encourage countries to report new outbreaks quickly without fear of economic sanctions.
- Health Justice: Addresses the structural imbalance where LMICs provide the raw material (data) and rich countries take the profit.
- Decentralized Production: Encourages regional manufacturing hubs in Africa, Asia, and Latin America through tech transfers.
- Unified Response: Prevents fragmented systems by bringing all pathogens under a single WHO-governed legal structure.
⚠️ Challenges
- Pharma Opposition: Large pharmaceutical companies argue that mandatory sharing discourages private investment and innovation.
- Enforcement Difficulties: Difficulty in tracking digital sequence information (DSI) makes it hard to link a specific vaccine back to a specific sample.
- Bureaucratic Delays: Over-regulation could potentially slow down the scientific response during the early days of a pandemic.
- Sovereignty Issues: Some nations may view global pathogen governance as an interference in their national health policies.
- Binding Obligations: Move away from voluntary gestures toward specific percentages (like the proposed 20%) for WHO stock.
- Tiered System: Implement different levels of commitments based on whether it is a peaceful period or a declared international emergency.
- Digital Traceability: Utilize blockchain or advanced databases to track how genetic data is used in research and development.
- Capacity Building: Instead of just vaccines, developed nations must provide the technology and training for local labs in LMICs.
- Trust as Public Infrastructure: Use the concept of 'Institutional Trust' when writing about why LMICs are hesitant to share pathogen data.
- Global South Solidarity: Mention how India and South Africa led the push for TRIPS waivers during COVID-19 as a precedent.
- Public vs Private Interest: Highlight the ethical dilemma of profit-driven innovation versus public good-oriented distribution.
- Data Sovereignty: Discuss how digital sequence information (DSI) has become the new 'resource wealth' of developing nations.
- The 20% Clause: Refer to the specific demand by LMICs for WHO to manage 10% of vaccines as a gift and 10% at cost price.
🧾 Conclusion
The current negotiations over PABS represent a historical moment for global governance. If successful, it would replace a system based on 'charity' with one based on 'legally binding equity.' Bridging the trust deficit between the Global North and South is essential for human security. As we prepare for 'Disease X,' the lesson is clear: no one is safe until everyone is safe. A strong PABS framework ensures that pathogens are shared not as a favor, but as part of a mutual pact for global survival.
About the Author
AKB is a UPSC educator focusing on Editorial Analysis, GS Mains preparation, Economy and Current Affairs.
📚 UPSC Previous Year Questions
- Critically analyze the role of the World Health Organization (WHO) in managing global health emergencies with reference to recent pandemics.
- Discuss the challenges in achieving 'Equity in Healthcare' in developing nations. How can international cooperation mitigate these issues?
- To what extent do intellectual property rights conflict with the human right to health in developing economies?
🔄 Cause-Effect Flowchart
- Outbreak detected in LMIC country.
- LMIC shares pathogen samples/data with global network.
- Global North scientists use data to develop vaccines/tech.
- Pharma companies claim IP and prioritize rich-nation markets.
- PABS intervention: Tech transfer and mandatory WHO reserve.
- Equitable distribution ensures LMICs get immediate supplies.
- Outcome: Global virus containment and reduced mutation risk.
📊 Important Data & Reports
- More than 70% of vaccines during the peak of COVID-19 were consumed by just 10 high-income countries.
- LMICs contribute roughly 60-80% of novel pathogen genetic sequence data to global databases.
- Over 100 countries currently support some form of TRIPS waiver or mandatory PABS commitments.
- The proposed WHO quota: 20% of medical products to be reserved for global health emergencies.
📝 Mains Answer (150 words)
Discuss how 'Vaccine Nationalism' creates obstacles for effective pandemic management.Vaccine nationalism occurs when countries prioritize their own population's access to vaccines over global need. This hampers management because: (1) It allows the virus to circulate freely in under-vaccinated regions, leading to mutations. (2) It disrupts global supply chains and economic recovery. (3) It breaks international trust, causing nations to withhold local pathogen data, which slows down global research.
📝 Mains Answer (250 words)
The conflict between Intellectual Property (IP) rights and benefit sharing is at the heart of global health governance. Examine this statement with respect to the proposed WHO Pandemic Treaty.The statement highlights the core tension in modern medicine. The IP perspective: Pharma companies argue patents incentive huge investments (R&D) and guarantee quality. Without IP protection, innovation may stall. The Benefit Sharing perspective: Since pathogens are often 'national resources' of developing countries, those countries deserve a share in the finished product. The Pandemic Treaty aims to bridge this by: (1) Proposing a 20% global reservation of supplies. (2) Encouraging tiered pricing models. (3) Creating transparent licensing for local producers. The challenge lies in making these rules legally binding while maintaining incentives for innovation. Ultimately, global health equity requires seeing medicines as public goods rather than just commodities.
❓ Prelims MCQs
Which existing international agreement specifically focuses on 'Access and Benefit Sharing' of generic resources?(a) Montreal Protocol (b) Nagoya Protocol (c) Paris Agreement (d) Geneva Convention
Answer: (b)
Explanation: The Nagoya Protocol is a supplementary agreement to the Convention on Biological Diversity (CBD). It provides a legal framework for the fair and equitable sharing of benefits arising out of the utilization of genetic resources.
What percentage of real-time production has been proposed to be allocated to WHO under the PABS negotiations for pandemic response?(a) 10% (b) 20% (c) 50% (d) 5%
Answer: (b)
Explanation: Negotiators have proposed that at least 20% of pandemic-related health products should be allocated to WHO for equitable distribution.
❓ FAQs
Is Pathogen Access and Benefit Sharing currently a law?
No, it is currently a set of proposals being negotiated as part of the broader WHO Pandemic Treaty or Agreement.
Why do pharma companies oppose mandatory benefit sharing?
They argue that mandatory requirements like tech transfer and set prices lower their profits and may compromise the safety and speed of drug development.
How does India stand on PABS?
India generally supports equitable sharing and decentralized manufacturing, advocating for the rights of the Global South to access life-saving tech without excessive patent barriers.
- Global Health Governance Explained
- Understanding TRIPS and Pharma
- Indian Healthcare Sector and Challenges
- Sustainable Development Goal 3 Progress